| Interrupted aortic arch | |
|---|---|
| Specialty |
Cardiology 
|
Interrupted aortic arch is a very rare heart defect (affecting 3 per million live births) in which the aorta is not completely developed. There is a gap between the ascending and descending thoracic aorta. In a sense it is the complete form of a coarctation of the aorta. Almost all patients also have other cardiac anomalies, including a ventricular septal defect (VSD), aorto-pulmonary window, and truncus arteriosus. There are three types of interrupted aortic arch, with type B being the most common. Interrupted aortic arch (especially Type B) is often associated with DiGeorge syndrome.
Signs and symptoms
Patients with an interrupted aortic arch usually have symptoms from birth, with nearly all presenting symptoms within two weeks (when the ductus arteriosus is usually closed).
Causes
It is thought that an interrupted aortic arch occurs through excessive apoptosis in the developing, embryonic aorta. Around 50% of patients have DiGeorge syndrome.
Diagnosis
It can be diagnosed with a standard echocardiogram. An echocardiogram can also aid in classifying the type of defect. The diagnosis can also be made prior to birth via ultrasound. Patients will have a loss of appetite, appear tired and weak, and exhibit rapid breathing and a rapid heart rate. If the condition progresses, the infant may turn pale, feel cold in the lower half of the body, and have a weak pulse due to insufficient blood flow. The pattern of pulse abnormalities is dependent upon the classification; e.g., for type B interrupted aortic arch, the right brachial pulse will be palpable and the left brachial and femoral pulses will be impalpable due to closure of the ductus arteriosus. Rarely, an interrupted aortic arch can be associated with an intracranial aneurysm. Signs of ischemia due to interrupted aortic arch can be separated by the organ system involved:
- Liver injury: elevated serum glutamic oxaloacetic transaminase (SGOT) (also known as aspartate transaminase, AST) and lactic acid dehydrogenase (LDH)
- Kidney injury: elevated serum creatinine
- Intestinal injury: signs of necrotizing enterocolitis, such as bloody stools
CHARGE syndrome, a specific, rare pattern of genetic abnormalities, commonly features conotruncal and aortic arch heart defects, which can include an interrupted aortic arch.
Classification
There are three primary classifications for an interrupted aortic arch, on the basis of the specific, anatomic anomaly. They are:
- Type A: The aortic arch is interrupted after the left subclavian artery.
- Type B: The aortic arch is interrupted between the left common carotid artery and the left subclavian artery. This is the most common form of the condition, and is the classification most often associated with DiGeorge syndrome.
- Type C: The aortic arch is interrupted between the innominate artery and the left common carotid artery. This is the least common form of the condition.
Each class can be divided into two subgroups, based upon whether the right subclavian artery originated in a normal, anatomical position (subgroup 1) or if it originated distal to the left subclavian artery and continues behind the esophagus (subgroup 2). However, these subgroups do not affect how the disease is diagnosed or treated.
Treatment
Prostaglandins
If the diagnosis is made prenatally, prostaglandin E1 (PGE1) is started after birth to avoid closure of the ductus arteriosus. Prostaglandin therapy is performed via a continuous infusion, due to how quickly prostaglandins are metabolized in the body. However, the diagnosis may go undetected, delaying treatment until closure of the ductus arteriosus produces symptoms.
Surgery
Curative treatment consists of open heart surgery soon after birth, preferably immediately after diagnosis. Often, a synthetic patch is used to recreate the lost section of aorta. Recent research has revealed that an initial single-stage repair using direct anastomoses and repair of any existing cardiac defects is the preferred surgical technique, as opposed to a two-stage surgical repair. Awaiting surgery, prostaglandin can be administered to keep the ductus arteriosus open, thereby allowing blood flow to the lower body. After successful treatment, the patient is monitored for the rest of their life by a specialist to ensure that problems do not occur.
Prognosis
Failure to treat the condition yields a mortality rate of 90% at a median age of 4 days. Death occurs due to increased blood flow from the left side of the heart (oxygenated blood) to the right side (deoxygenated blood), inducing heart failure; pulmonary edema; and eventual closing of the ductus arteriosus. For an infant with an interrupted aortic arch, a patent (open) ductus arteriosus allows for blood to bypass the "interruption," without which blood will be unable to reach the lower half of the body. As a result, the kidneys fail and the blood becomes acidic, resulting in death.
With modern surgical techniques, 81% of children with an interrupted aortic arch survive to be 15 years-old. The fate of survivors in the long-term is still unclear.
Surgical complications
The most common, early complication of surgery is bleeding, the risk of which can be increased by prematurity, prolonged acidosis prior to surgery, and excessive tension on the anastamosis due to inadequate mobilization of the ascending and descending aorta. Other early complications include damage to the left recurrent laryngeal nerve and the phrenic nerve. Late complications include obstruction of the graft and obstruction of the left main bronchus (which passes underneath the aortic arch).
Epidemiology
The incidence of an interrupted aortic arch is extremely rare, occurring between three and twenty times per 1,000,000 births. In the context of other congenital cardiac abnormalities, interrupted aortic arch represents about 1.5% of cases.
History
The condition was first identified by Dr. Raphael Steidele, Professor of Obstetrics at the University of Vienna, in 1778. In the case Steidele described, the infant had a type A interrupted aortic arch, and survived only for "a few hours." In homage to the discoverer, the terminology of "Steidele's complex" has been used to describe an interrupted aortic arch. The first type B interrupted aortic arch was reported by Seidel in 1818, and the first type C was reported by Weisman and Kesten in 1948. The classification system (Types A, B, and C) were defined by Celoria and Patton in 1959.
The first successful repair of a Type A interrupted aortic arch was reported in 1961, in which the left subclavian artery was grafted into the descending thoracic aorta in a 14-year-old male patient. The first successful repair of a Type A interrupted aortic arch in an infant was in a 12-day-old infant in 1969, in which the left subclavian artery was connected to the descending thoracic aorta, the patent ductus arteriosus was closed, and the main pulmonary artery was banded.
The first successful repair of a Type B interrupted aortic arch was in 1954, in which the 16 year-old, female patient's own aorta was grafted from the arch to the descending thoracic aorta and the left subclavian artery was ligated. The first successful repair on a type B interrupted aortic arch in an infant was in 1973, in which a vein was used to connect the ascending aorta and the descending aorta.
The first successful repair of a Type C interrupted aortic arch was in 1964, in which the 16-year-old female patient's ascending aorta was grafted to the descending thoracic aorta. As of 1984, there had been no successful repairs on infants under one year old.
The use of PGE1 dramatically improved the mortality rate after its introduction in 1976.
Research directions
While PGE1 is the standard of care for maintaining the ductus arteriosus, there is insufficient data on the proper dose, duration of therapy, safety, and long-term consequences of PGE1 on infants with ductal-dependent congenital heart defects (like interrupted aortic arch).
Further reading
- Collins-Nakai, RL; Dick, M; Parisi-Buckley, L; Fyler, DC; Castaneda, AR (1976). "Interrupted aortic arch in infancy". The Journal of Pediatrics. 88 (6): 959–62. doi:10.1016/S0022-3476(76)81049-9. PMID 1271195.